Prescripción de glucosamina para la osteoartritis y sus efectos en personas con diabetes
Resumen
La glucosamina es un suplemento nutricional de amplio consumo como tratamiento de la osteoartritis, aunque según estudios bien diseñados no existe evidencia firme de su efectividad clínica sobre esa enfermedad. Se considera un producto seguro en población general, pero es un amino monosacárido que parece tener efectos adversos en el metabolismo glucídico de sujetos con resistencia a insulina. Su aparente inocuidad en personas con diabetes controlada y de corto tiempo de evolución, no puede extrapolarse a toda la población con diabetes, y menos a aquellos en riesgo potencial de padecerla. El enfoque de este trabajo persigue desalentar la prescripción irracional de glucosamina en presencia de trastornos glucídicos, hasta tanto no estén disponibles estudios que avalen la seguridad de su consumo en este grupo particular de pacientes.
Palabras clave
Referencias
Abate M, Schiavone C, Pelotti P, Salini V. Limited joint mobility in diabetes and ageing: recent advances in pathogenesis and therapy. Int J Immunopathol Pharmacol. 2010;23(4):997-1003.
Black C, Clar C, Henderson R, MacEachern C, McNamee P, Quayyum Z, et al. The clinical effectiveness of glucosamine and chondroitin supplements in slowing or arresting progression of osteoarthritis of the knee: a systematic review and economic evaluation. Health Technol Assess. 2009;13(52):1-148.
Silbert JE. Dietary glucosamine under question. Glycobiology. 2009;19(6):564-7.
Wandel S, Jüni P, Tendal B, Nüesch E, Villiger PM, Welton NJ, et al. Effects of glucosamine, chondroitin, or placebo in patients with osteoarthritis of hip or knee: network meta-analysis. BMJ. 2010;341:c4675.
Jain RK, McCormick JC. Can glucosamine supplements be applied for all patients with type 2 diabetes with osteoarthritis? Arch Intern Med. 2004;164(7):807.
Marshall PD, Poddar S, Tweed EM, Brandes L. Clinical inquiries: Do glucosamine and chondroitin worsen blood sugar control in diabetes? J Fam Pract. 2006;55(12):1091-3.
Stumpf JL, Lin SW. Effect of glucosamine on glucose control. Ann Pharmacother. 2006;40(4):694-8.
Muniyappa R. Glucosamine and osteoarthritis: time to quit? Diabetes Metab Res Rev. 2011;27(3):233-4.
Samson DJ, Grant MD, Ratko TA, Bonnell CJ, Ziegler KM, Aronson N. Treatment of primary and secondary osteoarthritis of the knee. Evid Rep Technol Assess (Full Rep). 2007;(157):1-157.
Gouze JN, Gouze E, Popp MP, Bush ML, Dacanay EA, Kay JD, et al. Exogenous glucosamine globally protects chodrocytes from the arthritogenic effects of IL-1beta. Arthritis Res Ther. 2006;8(6):R173.
Uitterlinden EJ, Jahr H, Koevoet JL, Jenniskens YM, Bierma-Zeinstra SM, Degroot J, et al. Glucosamine decreases expression of anabolic and catabolic genes in human osteoarthritic cartilage explants. Osteoarthritis Cartilage. 2006;14(3):250-7.
Meulyzer M, Vachon P, Beaudry F, Vinardell T, Richard H, Beauchamp G, et al. Comparison of pharmacokinetics of glucosamine and synovial fluid levels following administration of glucosamine sulfate or glucosamine hydrochloride. Osteoarthritis Cartilage. 2008;16(9):973-79.
Bruyere O, Reginster JY. Glucosamine and chondroitin sulfate as therapeutic agents for knee and hip osteoarthritis. Drugs Aging. 2007;24(7):573-80.
Vangsness CT, Spiker W, Erickson J. A review of evidence-based medicine for glucosamine and chondroitin sulfate use in knee osteoarthritis. Arthroscopy. 2009;25(1):86-94.
Clegg DO, Reda DJ, Harris CL, Klein MA, O'Dell JR, Hooper MM, et al. Glucosamine, chondroitin sulfate, and the two in combination for painful knee osteoarthritis. N Engl J Med. 2006;354(8):795-808
Fox BA, Stephens MM. Glucosamine hydrochloride for the treatment of osteoarthritis symptoms. Clin Interv Aging. 2007;2(4):599-604.
Towheed TE, Maxwell L, Anastassiades TP, Shea B, Houpt J, Robinson V, et al. Glucosamine therapy for treating osteoarthritis. Cochrane Database Syst Rev. 2005;18(2):CD002946.
Anderson JW, Nicolosi RJ, Borzelleca JF. Glucosamine effects in humans: a review of effects on glucose metabolism, side effects, safety considerations and efficacy. Food Chem Toxicol. 2005;43(2):187-201.
Dostrovsky NR, Towheed TE, Hudson RW, Anastassiades TP. The effect of glucosamine on glucose metabolism in humans: a systematic review of the literature. Osteoarthritis Cartilage. 2011;19(4):375-80.
Hussain MA. A case for glucosamine. Eur J Endocrinol. 1998;139(5):472-5.
Tannis AJ, Barban J, Conquer JA. Effect of glucosamine supplementation on fasting and non-fasting plasma glucose and serum insulin concentrations in healthy individuals. Osteoarthritis Cartilage. 2004;12(6):506-11.
Pham T, Cornea A, Blick KE, Jenkins A, Scofield RH. Oral glucosamine in doses used to treat osteoarthritis worsens insulin resistance. Am J Med Sci. 2007;333(6):333-9.
Biggee BA, Blinn CM, Nuite M, Silbert JE, McAlindon TE. Effects of oral glucosamine sulphate on serum glucose and insulin during an oral glucose tolerance test of subjects with osteoarthritis. Ann Rheum Dis. 2007;66(2):260-2.
Albert SG, Oiknine RF, Parseghian S, Mooradian AD, Haas MJ, Mcpherson T. The effect of glucosamine on serum HDL cholesterol and apolipoprotein AI levels in people with diabetes. Diabetes Care. 2007;30(11):2800–3.
Scroggie DA, Albright A, Harris MD. The effect of glucosamine-chondroitin supplementation on glycosylated hemoglobin levels in patients with type 2 diabetes mellitus. Arch Intern Med. 2003;163(13):1587-90
Simon RR, Marks V, Leeds AR, Anderson JW. A comprehensive review of oral glucosamine use and effects on glucose metabolism in normal and diabetic individuals. Diabetes Metab Res Rev. 2011;27(1):14-27.
Enlaces refback
- No hay ningún enlace refback.
FINLAY EN:
FINLAY CERTIFICADA POR:
Esta revista "no aplica" cargos por publicación en ninguna etapa del proceso editorial.
Dirección postal: Calle 51A y Avenida 5 de Septiembre Cienfuegos, Cuba Código postal: 55100.
http://www.revfinlay.sld.cu
Telefono: +53 43 516602. Telefax: +53 43 517733.
amgiraldoni@infomed.sld.cu
ISSN: 2221-2434
RNPS: 5129